Last Call: Register for Creative Biolabs’ Free Webinar and Learn What’s New in siRNA Therapy

November 10 18:41 2021
Creative Biolabs will hold a free live webinar in Nov. 2021, inviting Dr. Markita Landry to discuss Optimal Therapeutic Intervention Timepoints for siRNA-Based Huntington’s Disease Therapies.

New York, USA – November 10, 2021 – Gene therapy is a potential therapeutic platform as it targets disease-causing genes based on their sequence, allowing for more accurate and individualized treatment of a variety of life-threatening diseases. RNA interference (RNAi) is an ancient biological mechanism to defend against external invasion, and small interfering RNA (siRNA) is regarded as a promising therapeutic modality since it theoretically can silence any disease-related genes in a sequence-specific manner.

With the self-developed GTOnco™ gene therapy platform, Creative Biolabs’ extensive expertise covers immuno-oncology (I-O) drug development spanning all phases, ranging from prove-of-concept assays to Investigational New Drug (IND) application. Especially, the expert team at Creative Biolabs realizes the underdeveloped potential of gene therapy, and is dedicated to advancing and facilitating related research of worldwide clients.

In addition to a comprehensive portfolio of services and products regarding gene therapy, a webinar series program is in full swing with the upcoming webinar inviting Dr. Markita Landry as the featured speaker.

Dr. Markita Landry has forged numerous high-profile partnerships since establishing the Landry Lab in the Dept. of Chemical and Biochemical Engineering at the University of California, Berkeley in 2016. Her team centers on the development of synthetic nanoparticle-polymer conjugates for imaging neuromodulation in the brain, and for the delivery of functional biomolecules and nutrients into living systems. Dr. Markita has won multiple awards for her innovative research, including the 2020 Society for Neuroscience Janett Rosenberg Trubatch Career Award and the 2022 Vilcek Prize for Creative Promise.

It is a privilege for Creative Biolabs to invite Dr. Markita to share the latest findings on siRNA therapy for Huntington’s disease (HD) in the upcoming webinar in Nov. 2021. The basic information is listed below.

Webinar Info

Subject: Optimal Therapeutic Intervention Timepoints for siRNA-Based Huntington’s Disease Therapies

Time: 12:00 PM PST | 3:00 PM EST, November 23, 2021

Charge: Free

Key Points:

1. The development of nIRCat that can be used to image “hot spots” of dopamine activity in the striatum of R6/2 HD model mice;

2. How to use the findings as optimal therapeutic intervention timepoints for siRNA-based HD therapies;

3. How dopaminergic projections are affected by mutant huntingtin, and whether specific targeting of these loci is important for developing gene therapy efforts.

More information about the webinar series about gene therapy or services and products at Creative Biolabs can be found at https://www.creative-biolabs.com/gene-therapy.

About Creative Biolabs

With years of experience in providing one-stop preclinical development service, Creative Biolabs has built a team of expertise of solid knowledge of gene therapy, and is fully competent in providing services for worldwide clients. The services include but are not limited to delivery vehicles development, gene editing for gene therapy, RNAi therapy development, safety and toxicology analysis, potency tests, and solutions of specific gene therapy development for diseases.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy

  Categories: